Tag: Immunotherapy
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months
Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients
Fifteen of 20 HLA-matched living donor recipients achieved the primary end point of being immunosuppression-free for more than two years
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
Introduction of immune checkpoint inhibitors linked to widening disparity for those with private insurance versus those without insurance
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival
FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma
Significantly improved progression-free survival seen with Monjuvi in combination with rituximab and lenalidomide
Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
Patients belonging to haplogroup T exhibit unique nivolumab-resistant baseline peripheral CD8+ T-cell repertoire
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer
Longer mean duration of quality-adjusted time without symptoms of disease progression or toxicity of treatment seen with dostarlimab
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
Better event-free survival outcomes seen for durvalumab plus FLOT versus FLOT alone in phase 3 randomized trial
FDA Approves Zynyz as First-Line Treatment for Advanced Anal Cancer
The programmed death receptor-1-blocking antibody is approved as a single agent or in combination with chemotherapy
Adding Bevacizumab to Chemo Beneficial in High-Risk Ovarian Cancer
Real-world benefit seen with addition of bevacizumab to first-line chemotherapy for patients with high‐risk prognostic factors
